Video

Dr. Lee on Early Efficacy Data With Cirmtuzumab/Ibrutinib in MCL

Author(s):

Hun Ju Lee, MD, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib in patients with relapsed/refractory mantle cell lymphoma.

Hun Ju Lee, MD, an associate professor of medicine in the Department of Lymphoma & Myeloma and the Jessica and Jeffrey Brue Endowed Professor of Lymphoma Research at The University of Texas MD Anderson Cancer Center, discusses early efficacy data from a phase 1b/2 study of the investigational ROR1 inhibitor cirmtuzumab in combination with ibrutinib (Imbruvica) in patients with relapsed/refractory mantle cell lymphoma (MCL).

At the 2020 ASCO Virtual Scientific Program, interim results showed that the combination led to an 83.3% overall response rate in 12 patients with relapsed/refractory MCL, says Lee. Moreover, 7 patients achieved a complete response, and 3 patients achieved a partial response.

Additionally, of the 7 patients who achieved a CR, 2 had progressed on rituximab (Rituxan)/ibrutinib and rituximab/ hyperfractionated cyclophosphamide, vincristine, doxorubicin hydrochloride, and dexamethasone, 1 patient previously underwent an autologous stem cell transplant and an allogeneic stem cell transplant (allo-SCT), and 1 patient underwent an allo-SCT and received CAR T-cell therapy.

Additionally, only grade 1/2 adverse effects related to cirmtuzumab were noted, and the safety profile of ibrutinib was as expected, concludes Lee.

Related Videos
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS